

## CV Abreviado Jacqueline Mayoral van Son

Licenciada en Medicina y Cirugía por la Universidad de Salamanca en 2001.

Especialista en psiquiatría Hospital Universitario Marqués de Valdecilla, Santander en 2006.

Estancia externa en Unidad de trastornos afectivos resistentes Universidad de Newcastle , Reino Unido ( Enero 2006-Mayo 2006).

Ha trabajado como FEA Psiquiatría en Hospital Universitario Marqués de Valdecilla, Santander (2006-2009) siendo coordinadora de la Unidad de Salud Mental Pas-Miera durante 3 años y posteriormente (2009-2019) ha realizado su labor clínica en el Servicio de Psiquiatría del Hospital de Sierrallana, Torrelavega, en Cantabria.

Doctora en Psiquiatría por la Universidad por la Universidad de Cantabria (2016).

Máster en Psicoterapia Integradora por la Universidad de Alcalá de Henares (2008-2011) y Especialista en Psiquiatría Forense UNED (2008).

Curso de Gestión Clínica de Servicios en Salud Mental (EADA) (2008).

Título de Experto en TDAH en el adulto por la Universidad de Alcalá (2019).

Actualmente ocupa el puesto de Subdirectora Médica en el Hospital Universitario Virgen del Rocío , en Sevilla desde Junio del 2020.

FEA del HUVR de Sevilla plaza en propiedad desde Junio 2021. Grado III carrera profesional.

Es investigadora colaboradora en el grupo G26 del CIBERSAM, y ha colaborado a nivel asistencial e investigador en el Programa de Atención a las Fases Iniciales de Psicosis (PAFIP) de Cantabria. Ha sido coordinadora del Programa de Atención a Primeros Episodios de Trastorno Bipolar JANO, del Hospital Universitario Marqués de Valdecilla,

Santander (2006-2009). Investigadora perteneciente al IDIVAL, Cantabria, desde el 2016-2020.

Sus áreas de interés a nivel investigador son aspectos clínicos, evolutivos y económicos en Primeros episodios de Psicosis no afectivas, y en primeros episodios de Trastorno Bipolar.

Premio al mejor Poster en Neuropsicofarmacología en el CNP 2022 por la Sociedad Española de Psiquiatría y Salud mental.

Profesora colaboradora en la Universidad de Cantabria, facultad de Medicina y en el MASTER Interuniversitario en Iniciación a la Investigación en Salud Mental ( 2012-2023).

Asistente honoraria del departamento de psiquiatría de la Universidad de Sevilla Facultad de Medicina desde Septiembre 2023.

Profesora invitada colaboradora externa asignatura Dolor en la Practica Médica del Departamento de Cirugía Universidad de Sevilla desde Marzo del 2021.

Publicaciones :

1. [The genetic architecture of the human cerebral cortex.](#)

Grasby KL, Jahanshad N, Painter JN, Colodro-Conde L, Bralten J, Hibar DP, Lind PA, Pizzagalli F, Ching CRK, McMahon MAB, Shatikhina N, Zsembik LCP, Thomopoulos SI, Zhu AH, Strike LT, Agartz I, Alhusaini S, Almeida MAA, Alnæs D, Amlie-von IK, Andersson M, Ard T, Armstrong NJ, Ashley-Koch A, Atkins JR, Bernard M, Brouwer RM, Buimer EEL, Bülow R, Bürger C, Cannon DM, Chakravarty M, Chen Q, Cheung JW, Couvy-Duchesne B, Dale AM, Dalvie S, de Araujo TK, de Zubicaray GI, de Zwarte SMC, den Braber A, Doan NT, Dohm K, Ehrlich S, Engelbrecht HR, Erk S, Fan CC, Fedko IO, Foley SF, Ford JM, Fukunaga M, Garrett ME, Ge T, Giddaluru S, Goldman AL, Green MJ, Groenewold NA, Grotegerd D, Gurholt TP, Gutman BA, Hansell NK, Harris MA, Harrison MB, Haswell CC, Hauser M, Herms S, Heslenfeld DJ, Ho NF, Hoehn D, Hoffmann P, Holleran L, Hoogman M, Hottenga JJ, Ikeda M, Janowitz D, Jansen IE, Jia T, Jockwitz C, Kanai R, Karama S, Kasperaviciute D, Kaufmann T, Kelly S, Kikuchi M, Klein M, Knapp M, Knodt AR, Krämer B, Lam M, Lancaster TM, Lee PH, Lett TA, Lewis LB, Lopes-Cendes I, Luciano M, Macciardi F, Marquand AF, Mathias SR, Melzer TR, Milaneschi Y, Mirza-Schreiber N, Moreira JCV, Mühleisen TW, Müller-Myhsok B, Najt P, Nakahara S, Nho K, Olde Loohuis LM, Orfanos DP, Pearson JF, Pitcher TL, Pütz B, Quidé Y, Ragothaman A, Rashid FM, Reay WR, Redlich R, Reinbold CS, Reppele J, Richard G, Riedel BC, Risacher SL, Rocha CS, Mota NR, Salminen L, Saremi A, Saykin AJ, Schlag F, Schmaal L, Schofield PR, Secolin R, Shapland CY, Shen L, Shin J, Shumskaya E, Sørnderby IE, Sprooten E, Tansey KE, Teumer A, Thalamuthu A, Tordesillas-Gutiérrez D, Turner JA, Uhlmann A, Vallerga CL, van der Meer D, van Donkelaar MMJ, van Eijk L, van Erp TGM, van Haren NEM, van Rooij D, van Tol MJ, Veldink JH, Verhoef E, Walton E, Wang M, Wang Y, Wardlaw JM, Wen W, Westlye LT, Whelan CD, Witt SH, Wittfeld K, Wolf C, Wolfers T, Wu JQ, Yasuda CL, Zaremba D, Zhang Z, Zwiens MP, Artiges E, Assareh AA, Ayesa-Arriola R, Belger A, Brandt CL, Brown GG, Cichon S, Curran JE, Davies GE, Degenhardt F, Dennis MF, Dietsche B, Djurovic S, Doherty CP, Espiritu R, Garijo D, Gil Y, Gowland PA, Green RC, Häusler AN, Heindel W, Ho BC, Hoffmann WU, Holsboer F, Homuth G, Hosten N, Jack CR Jr, Jang M, Jansen A, Kimbrel NA, Kolskår K, Koops S, Krug A, Lim KO, Luyckx JJ, Mathalon DH, Mather KA, Mattay VS, Matthews S, **Mayoral Van Son J**, McEwen SC, Melle I, Morris DW, Mueller BA, Nauck M, Nordvik JE, Nöthen MM, O'Leary DS, Opel N, Martinot MP, Pike GB, Preda A, Quinlan EB, Rasser PE, Ratnakar V, Reppermund S, Steen VM, Tooney PA, Torres FR, Veltman DJ, Voyvodic JT, Whelan R, White T, Yamamori H, Adams HHH, Bis JC, Dobbins S, Decarli C, Fornage M, Gudnason V, Hofer E, Ikram MA,

Launer L, Longstreth WT, Lopez OL, Mazoyer B, Mosley TH, Roshchupkin GV, Satizabal CL, Schmidt R, Seshadri S, Yang Q; Alzheimer's Disease Neuroimaging Initiative; CHARGE Consortium; EPIGEN Consortium; IMAGEN Consortium; SYS Consortium; Parkinson's Progression Markers Initiative; Alvim MKM, Ames D, Anderson TJ, Andreassen OA, Arias-Vasquez A, Bastin ME, Baune BT, Beckham JC, Blangero J, Boomsma DI, Brodaty H, Brunner HG, Buckner RL, Buitelaar JK, Bustillo JR, Cahn W, Cairns MJ, Calhoun V, Carr VJ, Caseras X, Caspers S, Cavalleri GL, Cendes F, Corvin A, Crespo-Facorro B, Dalrymple-Alford JC, Dannlowski U, de Geus EJC, Deary IJ, Delanty N, Depondt C, Desrivieres S, Donohoe G, Espeseth T, Fernández G, Fisher SE, Flor H, Forstner AJ, Francks C, Franke B, Glahn DC, Gollub RL, Grabe HJ, Gruber O, Håberg AK, Hariri AR, Hartman CA, Hashimoto R, Heinz A, Henskens FA, Hillegers MHJ, Hoekstra PJ, Holmes AJ, Hong LE, Hopkins WD, Hulshoff Pol HE, Jernigan TL, Jönsson EG, Kahn RS, Kennedy MA, Kircher TTJ, Kochunov P, Kwok JBJ, Le Hellard S, Loughland CM, Martin NG, Martinot JL, McDonald C, McMahon KL, Meyer-Lindenberg A, Michie PT, Morey RA, Mowry B, Nyberg L, Oosterlaan J, Ophoff RA, Pantelis C, Paus T, Pausova Z, Penninx BWJH, Polderman TJC, Posthuma D, Rietschel M, Roffman JL, Rowland LM, Sachdev PS, Sämann PG, Schall U, Schumann G, Scott RJ, Sim K, Sisodiya SM, Smoller JW, Sommer IE, St Pourcain B, Stein DJ, Toga AW, Trollor JN, Van der Wee NJA, van 't Ent D, Völzke H, Walter H, Weber B, Weinberger DR, Wright MJ, Zhou J, Stein JL, Thompson PM, Medland SE; Enhancing Neuroimaging Genetics through Meta-Analysis Consortium (ENIGMA)—Genetics working group. *Science*. 2020 Mar 20;367(6484):eaay6690. doi: 10.1126/science.aay6690. PMID: 32193296 Free PMC article.


2. [Reduced glomerular filter rate in antipsychotic-naïve patients with first-episode psychosis.](#) García-Rizo C, Ortiz García de la Foz V, **Mayoral-van Son J**, Gómez-Revuelta M, Juncal Ruiz M, Garrido-Torres N, Crespo-Facorro B, Vázquez-Bourgon J. *Schizophr Res*. 2022 Aug;246:202-204. doi: 10.1016/j.schres.2022.06.016. Epub 2022 Jul 5. PMID: 35802955 No abstract available.
3. [Ten-year course of cognition in first-episode non-affective psychosis patients: PAFIP cohort.](#) Rodríguez-Sánchez JM, Setién-Suero E, Suárez-Pinilla P, **Mayoral Van Son J**, Vázquez-Bourgon J, Gil López P, Crespo-Facorro B, Ayesa-Arriola R; PAFIP group. *Psychol Med*. 2022 Mar;52(4):770-779. doi: 10.1017/S0033291720002408. Epub 2020 Jul 20. PMID: 32686636
4. [Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics.](#) Montejo ÁL, Arango C, Bernardo M, Carrasco JL, Crespo-Facorro B, Cruz JJ, Del Pino-Montes J, García-Escudero MA, García-Rizo C, González-Pinto A, Hernández AI, Martín-Carrasco M, Mayoral-Cleries F, **Mayoral-van Son J**, Mories MT, Pachiarotti I, Pérez J, Ros S, Vieta E. *Front Neuroendocrinol*. 2017 Apr;45:25-34. doi: 10.1016/j.yfrne.2017.02.003. Epub 2017 Feb 21. PMID: 28235557 Review.
5. [Spanish consensus on the risks and detection of antipsychotic drug-related hyperprolactinaemia.](#) Montejo ÁL, Arango C, Bernardo M, Carrasco JL, Crespo-Facorro B, Cruz JJ, Del Pino J, García Escudero MA, García Rizo C, González-Pinto A, Hernández AI, Martín Carrasco M, Mayoral Cleries F, **Mayoral van Son J**, Mories MT, Pachiarotti I, Ros S, Vieta E. *Rev Psiquiatr Salud Ment*. 2016 Jul-Sep;9(3):158-73. doi: 10.1016/j.rpsm.2015.11.003. Epub 2016 Feb 24. PMID: 26927534 English, Spanish.
6. [Predictive value of prolactin in first episode psychosis at ten years follow-up.](#) Delgado-Alvarado M, Vázquez-Bourgon J, Ayesa-Arriola R, Foz VO, **Mayoral-van Son J**, Labad J, Crespo-Facorro B. *Rev Psiquiatr Salud Ment (Engl Ed)*. 2021 Jul-Sep;14(3):179-180. doi: 10.1016/j.rpsmen.2020.10.002. PMID: 34456033 No abstract available.
7. [Aripiprazole vs Risperidone Head-to-Head Effectiveness in First-Episode Non-Affective-Psychosis: A 3-Month Randomized, Flexible-Dose, Open-Label Clinical Trial.](#) Garrido-Sánchez L, Gómez-Revuelta M, Ortiz-García de la Foz V, Pelayo-Terán JM, Juncal-Ruiz M, Ruiz-Veguilla M, **Mayoral-Van Son J**, Ayesa-Arriola R, Vázquez-Bourgon J, Crespo-Facorro B. *Int J Neuropsychopharmacol*. 2022 Nov 17;25(11):900-911. doi: 10.1093/ijnp/pyac047. PMID: 35894865 Free PMC article. Clinical Trial.

8. [Current Data on and Clinical Insights into the Treatment of First Episode Nonaffective Psychosis: A Comprehensive Review.](#)  
Crespo-Facorro B, Pelayo-Teran JM, **Mayoral-van Son J**.  
Neurol Ther. 2016 Dec;5(2):105-130. doi: 10.1007/s40120-016-0050-8. Epub 2016 Aug 23.  
PMID: 27553839 Free PMC article. Review.
9. [Naturalistic study on the use of clozapine in the early phases of non-affective psychosis: A 10-year follow-up study in the PAFIP-10 cohort.](#)  
Moreno-Sancho L, Juncal-Ruiz M, Vázquez-Bourgon J, Ortiz-García de la Foz V, **Mayoral-van Son J**, Tordesillas-Gutiérrez D, Setien-Suero E, Ayesa-Arriola R, Crespo-Facorro B.  
J Psychiatr Res. 2022 Sep;153:292-299. doi: 10.1016/j.jpsychires.2022.07.015. Epub 2022 Jul 6.  
PMID: 35878537
10. [Aripiprazole and Risperidone Present Comparable Long-Term Metabolic Profiles: Data From a Pragmatic Randomized Controlled Trial in Drug-Naïve First-Episode Psychosis.](#)  
Vázquez-Bourgon J, Ortiz-García de la Foz V, Gómez-Revuelta M, **Mayoral-van Son J**, Juncal-Ruiz M, Garrido-Torres N, Crespo-Facorro B.  
Int J Neuropsychopharmacol. 2022 Oct 25;25(10):795-806. doi: 10.1093/ijnp/pyac033.  
PMID: 35641112 Free PMC article. Clinical Trial.
11. [Pattern of long-term weight and metabolic changes after a first episode of psychosis: Results from a 10-year prospective follow-up of the PAFIP program for early intervention in psychosis cohort.](#)  
Vázquez-Bourgon J, Gómez-Revuelta M, **Mayoral-van Son J**, Labad J, Ortiz-García de la Foz V, Setien-Suero E, Ayesa-Arriola R, Tordesillas-Gutiérrez D, Juncal-Ruiz M, Crespo-Facorro B.  
Eur Psychiatry. 2022 Aug 16;65(1):e48. doi: 10.1192/j.eurpsy.2022.2308.  
PMID: 35971658 Free PMC article.
12. [Long-term clinical and functional outcome after antipsychotic discontinuation in early phases of non-affective psychosis: Results from the PAFIP-10 cohort.](#)  
**Mayoral-van Son J**, Juncal-Ruiz M, Ortiz-García de la Foz V, Vázquez-Bourgon J, Setien-Suero E, Tordesillas-Gutiérrez D, Gómez-Revuelta M, Ayesa-Arriola R, Crespo-Facorro B; PAFIP Research Group.  
Schizophr Res. 2021 Jun;232:28-30. doi: 10.1016/j.schres.2021.04.011. Epub 2021 May 16.  
PMID: 34004383 No abstract available.
13. [Dissecting the functional outcomes of first episode schizophrenia spectrum disorders: a 10-year follow-up study in the PAFIP cohort.](#)  
Ayesa-Arriola R, Ortiz-García de la Foz V, Martínez-García O, Setien-Suero E, Ramírez ML, Suárez-Pinilla P, **Mayoral-van Son J**, Vázquez-Bourgon J, Juncal-Ruiz M, Gómez-Revuelta M, Tordesillas-Gutiérrez D, Crespo-Facorro B.  
Psychol Med. 2021 Jan;51(2):264-277. doi: 10.1017/S0033291719003179. Epub 2019 Nov 18.  
PMID: 31736458
14. [Treatment Discontinuation Impact on Long-Term \(10-Year\) Weight Gain and Lipid Metabolism in First-Episode Psychosis: Results From the PAFIP-10 Cohort.](#)  
Vázquez-Bourgon J, **Mayoral-van Son J**, Gómez-Revuelta M, Juncal-Ruiz M, Ortiz-García de la Foz V, Tordesillas-Gutiérrez D, Ayesa-Arriola R, Bioque M, Crespo-Facorro B.  
Int J Neuropsychopharmacol. 2021 Jan 20;24(1):1-7. doi: 10.1093/ijnp/pyaa066.  
PMID: 32840607 Free PMC article.
15. [Aripiprazole vs Risperidone for the acute-phase treatment of first-episode psychosis: A 6-week randomized, flexible-dose, open-label clinical trial.](#)  
Gómez-Revuelta M, Pelayo-Terán JM, Vázquez-Bourgon J, Ortiz-García de la Foz V, **Mayoral-van Son J**, Ayesa-Arriola R, Crespo-Facorro B.  
Eur Neuropsychopharmacol. 2021 Jun;47:74-85. doi: 10.1016/j.euroneuro.2021.02.009. Epub 2021 Mar 5.  
PMID: 33678469 Clinical Trial.
16. [A network analysis approach to functioning problems in first psychotic episodes and their relationship with duration of untreated illness: Findings from the PAFIP cohort.](#)  
Izquierdo A, Cabello M, de la Torre-Luque A, Ayesa-Arriola R, Setien-Suero E, **Mayoral-van-Son J**, Vázquez-Bourgon J, Ayuso-Mateos JL, Crespo-Facorro B; PAFIP Group Study.  
J Psychiatr Res. 2021 Apr;136:483-491. doi: 10.1016/j.jpsychires.2020.10.019. Epub 2020 Oct 22.  
PMID: 33129506

17. [Stability of schizophrenia diagnosis in a 10-year longitudinal study on first episode of non-affective psychosis: Conclusions from the PAFIP cohort.](#)  
Suárez-Pinilla P, Suárez-Pinilla M, Setién-Suero E, Ortiz-García de la Foz V, **Mayoral-Van Son J**, Vázquez-Bourgón J, Gómez-Revuelta M, Juncal-Ruiz M, Ayesa-Arriola R, Crespo-Facorro B. *Acta Psychiatr Scand.* 2021 Oct;144(4):342-357. doi: 10.1111/acps.13344. Epub 2021 Jul 21. PMID: 34228812
18. [Comparison of aripiprazole and risperidone effectiveness in first episode non-affective psychosis: Rationale and design of a prospective, randomized, 3-phase, investigator-initiated study \(PAFIP-3\).](#)  
**Son J MV**, Gómez-Revuelta M, Ayesa-Arriola R, Vázquez-Bourgón J, Foz VO, Ruiz-Veguilla M, Garrido N, Tordesillas-Gutiérrez D, Setién-Suero E, Crespo-Facorro B. *Rev Psiquiatr Salud Ment (Engl Ed).* 2021 Jul-Sep;14(3):157-163. doi: 10.1016/j.rpsmen.2021.08.002. PMID: 34456030 Clinical Trial.
19. [Predictors of weight acquisition induced by antipsychotic treatment and its relationship with age in a sample of first episode non-affective psychosis patients: A three-year follow-up study.](#)  
Canal-Rivero M, Ruiz-Veguilla M, Labad J, Ayesa-Arriola R, Vázquez-Bourgón J, **Mayoral-van Son J**, Setién-Suero E, Ortiz-García de la Foz V, Crespo-Facorro B; PAFIP research group. *Schizophr Res.* 2020 Aug;222:462-464. doi: 10.1016/j.schres.2020.06.011. Epub 2020 Jun 27. PMID: 32600780 No abstract available.
20. [Understanding the direct and indirect costs of a first episode of psychosis program: Insights from PAFIP of Cantabria, Spain, during the first year of intervention.](#)  
**Mayoral-van Son J**, Juncal-Ruiz M, Ortiz-García de la Foz V, Cantarero-Prieto D, Blázquez-Fernández C, Paz-Zulueta M, Paras-Bravo P, Ayuso-Mateos JL, Crespo-Facorro B. *Early Interv Psychiatry.* 2019 Oct;13(5):1182-1190. doi: 10.1111/eip.12752. Epub 2018 Oct 12. PMID: 30311416
21. [Cost of Relapse Management in Patients with Schizophrenia in Italy and Spain: Comparison Between Lurasidone and Quetiapine XR.](#)  
Restelli U, García-Goñi M, Lew-Starowicz M, Mierzejewski P, Silvola S, **Mayoral-van Son J**, Croce D, Rocca P, Crespo-Facorro B. *Clin Drug Investig.* 2020 Sep;40(9):861-871. doi: 10.1007/s40261-020-00944-0. PMID: 32648201 Free PMC article.
22. [A 3-year prospective study on the metabolic effect of aripiprazole, quetiapine and ziprasidone: A pragmatic clinical trial in first episode psychosis patients.](#)  
Vázquez-Bourgón J, Ibáñez Alario M, **Mayoral-van Son J**, Gómez Revuelta M, Ayesa Arriola R, Juncal Ruiz M, Ortiz-García de la Foz V, Crespo Facorro B. *Eur Neuropsychopharmacol.* 2020 Oct;39:46-55. doi: 10.1016/j.euroneuro.2020.08.009. Epub 2020 Sep 3. PMID: 32891516 Clinical Trial.
23. [Expression and Functionality Study of 9 Toll-Like Receptors in 33 Drug-Naïve Non-Affective First Episode Psychosis Individuals: A 3-Month Study.](#)  
Juncal-Ruiz M, Riesco-Davila L, Vazquez-Bourgón J, Ortiz-García de la Foz V, **Mayoral-Van Son J**, Ayesa-Arriola R, Setien-Suero E, Leza JC, Lopez-Hoyos M, Crespo-Facorro B. *Int J Mol Sci.* 2020 Aug 25;21(17):6106. doi: 10.3390/ijms21176106. PMID: 32854231 Free PMC article. Clinical Trial.
24. [Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals: a 3-year naturalistic follow-up study.](#)  
**Mayoral-van Son J**, de la Foz VO, Martínez-García O, Moreno T, Parrilla-Escobar M, Valdizan EM, Crespo-Facorro B. *J Clin Psychiatry.* 2016 Apr;77(4):492-500. doi: 10.4088/JCP.14m09540. PMID: 26759992
25. [Longitudinal trajectories in negative symptoms and changes in brain cortical thickness: 10-year follow-up study.](#)  
Canal-Rivero M, Ruiz-Veguilla M, Ortiz-García de la Foz V, López-Díaz A, Garrido-Torres N, Ayesa-Arriola R, Vazquez-Bourgón J, **Mayoral-van Son J**, Brambilla P, Kircher T, Romero-García R, Crespo-Facorro B. *Br J Psychiatry.* 2023 Feb 21:1-10. doi: 10.1192/bjp.2022.192. Online ahead of print.

PMID: 36805840

Sevilla 29 de noviembre 2023

A handwritten signature in blue ink, consisting of a large, stylized initial 'J' followed by a series of loops and a long horizontal stroke extending to the right.

Jacqueline Mayoral van Son